Wrap Text
Trading update and Mediclinic Middle East integration
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION
9 September 2016
TRADING UPDATE AND MEDICLINIC MIDDLE EAST INTEGRATION
Mediclinic International plc, the international private healthcare group (“Mediclinic” or the “Group”),
provides the following general update and further information in respect of the integration of the Al
Noor operations (“Al Noor”) and trading conditions for Mediclinic Middle East. Details of a conference
call with management at 8am BST are contained at the end of the release.
Since the beginning of the 2016/2017 financial year, Mediclinic has experienced trading conditions in
line with management’s expectations for its operations in Southern Africa, Switzerland and Dubai.
Significant progress has been made on integrating the businesses of Mediclinic International Limited
and Al Noor Hospitals Group plc (now renamed to Mediclinic International plc) since the combination
in February 2016, which created a leading private healthcare provider in the Middle East. A new
combined Mediclinic Middle East management team was established in March 2016 and a strategic
and operational review of the business was completed in early June 2016.
Work streams were established at the time of the combination to drive the integration process and
unlock synergies. These work streams are all progressing well and further synergies have been
identified resulting in a revised estimate of AED75m annualised cost synergies, ahead of the AED50m
previously communicated. The material benefit of the synergies will be realised in the second half of
the current financial year and more fully in the following financial years. A one-off cost of AED20m
associated with realising the cost synergies, to be excluded from underlying EBITDA, will be borne in
the current financial year with the majority in the first half.
Despite the good progress on integration, management believes that revenue growth in the Abu
Dhabi operations for the current financial year will be lower than previously expected principally for
the following reasons:
- The competition for quality clinical personnel in the region remains high, leading to inevitable
vacancies. The loss of doctors before completion of the combination has stabilised during the
period of integration. Management has aligned business practices and implemented a
recruitment process, in line with the Dubai operations.
- Daman, the leading health insurer, has instituted a 20% co-payment for Thiqa members using
private healthcare facilities from 1 July 2016 which is likely to have an impact on patient mix
and volumes. Mediclinic continues to engage with the relevant stakeholders in this regard.
- The delayed ramp up of new units including Al Jowhara is expected to impact 2016/17
revenues by AED75m. The 40 bed Al Jowhara Hospital in Al Ain will be commissioned in
October 2016, a delay of approximately six months.
As part of its review following the acquisition of Al Noor, management identified facilities that were
considered non-core to the business. Two units are in the process of being sold with further small
non-core disposals envisaged. The estimated revenue impact of the two units being sold is AED50m
in the 2016/2017 financial year.
In Dubai, the Mediclinic City Hospital North Wing expansion, creating an integrated oncology centre
as well as additional outpatient services and an additional 27 beds, is now operational. Despite the
delay in commissioning, trading in Dubai remains in line with management’s expectations.
Whilst expectations for the business in the medium term remain unchanged, and the process of
business integration continues, Mediclinic Middle East is now expected to deliver for the current
financial year ending 31 March 2017 low to mid-single digit revenue growth and underlying EBITDA
margins of mid to high teens with performance being materially second half weighted.
Danie Meintjes, CEO of Mediclinic International, commented:
“The combination of Mediclinic Middle East and Al Noor has created a leading private healthcare
platform with exposure to a region with highly attractive long-term sustainable growth opportunities.
Despite the short term challenges we are currently facing in Abu Dhabi, Mediclinic is well acquainted
with the process of business integration along with operational and business alignment. We remain
confident in the successful integration and growth of the business.
Trading in Mediclinic Southern Africa and Hirslanden remains in line with management’s
expectations.”
Pre-close trading update
The pre-close trading update for the five months ended 31 August 2016 will be provided in the last
week of September 2016, ahead of the publication of Mediclinic’s results on 10 November 2016 for
the six months ending 30 September 2016.
Analyst and investor conference call details
A conference call will be held at 8am BST this morning hosted by Danie Meintjes CEO and Jurgens
Myburgh CFO.
Participant dial in numbers are below:
United Kingdom 020 3059 8125
South Africa 0800 999 282
United Arab Emirates 8000 3570 2413
All other locations +44 20 3059 8125
Participants should state they wish to join the Mediclinic International conference call. Please dial in 5-
10 minutes prior to the call. A recording to the call will be made and will be accessible from
Mediclinic’s website www.mediclinic.com.
Registered address: 1st Floor, 40 Dukes Place, London, EC3A 7NH, United Kingdom
Website: www.mediclinic.com
JSE sponsor: RAND MERCHANT BANK (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd
For further information please contact:
Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
Bell Pottinger
Liz Morley/Aarti Iyer
+44 (0)203 772 2468
Date: 09/09/2016 08:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
